Nature Communications (Nov 2020)

CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

  • Man Zhang,
  • Wei Yang,
  • Peng Wang,
  • Yu Deng,
  • Yu-Ting Dong,
  • Fang-Fang Liu,
  • Rui Huang,
  • Peng Zhang,
  • Ya-Qi Duan,
  • Xin-Dong Liu,
  • Dandan Lin,
  • Qian Chu,
  • Bo Zhong

DOI
https://doi.org/10.1038/s41467-020-19973-6
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 17

Abstract

Read online

Only a limited proportion of patients with non-small cell lung cancer respond to anti-PD-1/PD-L1 immunotherapy. Here, the authors show that in autochthonous models of KRAS-mutated lung cancer, CCL7 promotes cDC1 infiltration into the lungs, sustaining antitumor immune responses and potentiating anti-PD1 treatment efficacy.